**7. Head and neck cancer and research hypothesis**

As the tools to categorize precancerous lesions in the mouth remain to improve, fewer men will die needlessly from head and neck cancer. Researchers are now harnessing the power of nanotechnology science to engineer strategies to investigate human fluids and tissues for abnormal molecules that are suggestive of a developing oral tumor. To detect abnormal cells and proteins in saliva that are associated with a developing oral tumor in-office diagnostic devices are being developed by investigators.

Treatment will improve, as targeted molecular therapy and personalized medicine become a truth. Predictable to guide treatment decisions for the individual patient on the basis of tumor HPV status is an evolving research, and evidence-based clinical trials are on the go. An inquiry is also defining the signaling pathways and networks that determine the development of head and neck cancer cells had been drawn, which will result in novel anticancer drugs that goals the particular molecular absences in each individual head and neck cancer patient.

[3] Iyer SG, Pradhan SA, Pai PS. Surgical treatment outcomes of localized squamous carci-

Introductory Chapter: Head and Neck Cancer http://dx.doi.org/10.5772/intechopen.86272 11

[4] Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. Journal of Clinical Oncology. 2006;**24**(14):2137-2150 [5] Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck

[6] Bray F, Ren JS, Masuyer E, Ferlay J. Estimates of global cancer prevalence for 27 sites in the adult population in 2008. International Journal of Cancer. 2013;**132**(5):1133-1145 [7] Amagasa T, Yamashiro M, Uzawa N. Oral premalignant lesions: From a clinical perspec-

[8] Napier SS, Speight PM. Natural history of potentially malignant oral lesions and conditions: An overview of the literature. Journal of Oral Pathology & Medicine. 2008;**37**(1):1-10 [9] Sankaranarayanan R, Ramadas K, Amarasinghe H, Subramanian S, Johnson N. Oral Cancer: Prevention, Early Detection, and Treatment. Disease Control Priorities. The World Bank, Washinton: The International Bank for Reconstruction and Development;

[10] Warnakulasuriya S, Johnson NW, Van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. Journal of Oral Pathology and

[11] Hsue SS, Wang WC, Chen CH, Lin CC, Chen YK, Lin LM. Malignant transformation in 1458 patients with potentially malignant oral mucosal disorders: A follow-up study based in a Taiwanese hospital. Journal of Oral Pathology and Medicine. 2007;**36**(1):25-29 [12] Bray F, Ferlay J, Laversanne M, Brewster DH, Gombe Mbalawa C, Kohler B, et al. Cancer incidence in five continents: Inclusion criteria, highlights from volume X and the global status of cancer registration. International Journal of Cancer. 2015;**137**(9):2060-2071 [13] Lambert R, Sauvaget C, Camargo CM, De, Sankaranarayanan R. Epidemiology of cancer from the oral cavity and oropharynx. European Journal of Gastroenterology and

[14] Bhurgri Y, Bhurgri A, Usman A, Pervez S, Kayani N, et al. Epidemiological review of head and neck cancers in Karachi. Asian Pacific Journal of Cancer Prevention.

[15] Tseng CH. Oral cancer in Taiwan: Is diabetes a risk factor? Clinical Oral Investigations.

[16] Brown LM, Check DP, Devesa SS. Oropharyngeal cancer incidence trends: Diminishing

[17] Saba NF, Goodman M, Ward K, Flowers C, Ramalingam S, et al. Gender and ethnic disparities in incidence and survival of squamous cell carcinoma of the oral tongue, base of tongue, and tonsils: A surveillance, epidemiology and end results program-based

racial disparities. Cancer Causes and Control. 2011;**22**(5):753-763

noma of buccal mucosa. Head and Neck. 2004;**26**(10):897-902

tive. International Journal of Clinical Oncology. 2011;**16**(1):5-14

cancer. Nature Reviews Cancer. 2011;**11**(1):9

3rd ed; 2015. p. 85

Medicine. 2007;**36**(10):575-580

Hepatology. 2011;**23**(8):633-641

analysis. Oncology. 2011;**81**(1):12-20

2006;**7**(2):195-200

2013;**17**(5):1357-1364

Head and neck cancers are readily accessible, unlike tumors of the prostate, pancreas, or other internal organs. Rapid growth of valuable information for developing improved cure rates for both oral and other cancers is attained, and becomes more effortlessly studied cancers which may allow to accomplish the goal.

Locoregional control and overall patient survival potentially may improve the development of novel chemotherapy regimens and targeted therapeutic agents. Groups, like the Eastern Cooperative Oncology Group (ECOG), Radiation Therapy Oncology Group (RTOG), Southwest Oncology Group (SWOG), and European Organization for the Research and Treatment of Cancer (EORTC), facilitate patient enrollment into multi-institutional prospective randomized trials, which have delivered us with the necessary data to define current and future standards of care. Measures to identify biomarkers that predict disease behavior will carry on as individualized therapy evolves. Endorsed quality-of-life index measures additional define treatment results, and escalation of combined treatment likely will necessitate significant attention regarding treatment-induced toxicities is to be looked upon [72, 73]. The use of tobacco-related foodstuffs remains important worldwide, but further etiologic factors such as HPV similarly affect HNSCC presentation, behavior, and treatment [74]. Though improvement has been made throughout the past 60 years, a boundless deal remains to be consummate in head and neck cancer prevention.
